Preparing for the Next Influenza Season: Monitoring the Emergence and Spread of Antiviral Resistance

References

• Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–1300. doi:10.1016/s0140-6736(17)33293-2
   PubMed Web of Science ®Google Scholar
• Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nat Rev Dis Primers. 2018;4(1):3. doi:10.1038/s41572-018-0002-y
   PubMed Web of Science ®Google Scholar
• Duwe SC, Schmidt B, Gärtner BC, et al. Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations. GMS Infect Dis. 2021;9:Doc02. doi:10.3205/id000071
   PubMedGoogle Scholar
• Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913–923. doi:10.1056/NEJMoa1716197
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020;383(4):309–320. doi:10.1056/NEJMoa1915341
   PubMed Web of Science ®Google Scholar
• Baker J, Block SL, Matharu B, et al. Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled Phase 3 safety and efficacy trial (miniSTONE-2). Pediatr Infect Dis J. 2020;39(8):700–705. doi:10.1097/inf.0000000000002747
   PubMed Web of Science ®Google Scholar
• Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204–1214. doi:10.1016/s1473-3099(20)30004-9
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Takashita E, Daniels RS, et al. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–2020. Antiviral Res. 2022;200:105281. doi:10.1016/j.antiviral.2022.105281
   PubMed Web of Science ®Google Scholar
• Lackenby A, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017. Antiviral Res. 2018;157:38–46. doi:10.1016/j.antiviral.2018.07.001
   PubMed Web of Science ®Google Scholar
• Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resist. 2017;10:121–134. doi:10.2147/idr.s105473
   PubMed Web of Science ®Google Scholar
• Oh DY, Buda S, Biere B, et al. Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January - September 2020: analysis of national surveillance data. Lancet Reg Health Europe. 2021;6:100112. doi:10.1016/j.lanepe.2021.100112
   PubMedGoogle Scholar
• Zhang Y, Yakob L, Bonsall MB, Hu W. Predicting seasonal influenza epidemics using cross-hemisphere influenza surveillance data and local internet query data. Sci Rep. 2019;9(1):3262. doi:10.1038/s41598-019-39871-2
   PubMedGoogle Scholar
• Australian Government, Department of Health and Age Care. Australian Influenza Surveillance Reports (AISR); 2022. Available from: https://www.health.gov.au/sites/default/files/documents/2022/10/aisr-fortnightly-report-no-14-26-september-to-9-october-2022.pdf. Accessed September 1, 2022.
   Google Scholar
• World Health Organization. Bi-weekly influenza situation update; Western Pacific Region. World Health Organization; 2022. Available from: https://www.who.int/docs/default-source/wpro---documents/emergency/surveillance/seasonal-influenza/influenza-20220727.pdf?sfvrsn=39dcc97a_103. Accessed July 27, 2022.
   Google Scholar
• Schulze M, Nitsche A, Schweiger B, Biere B, Liu DX. Diagnostic approach for the differentiation of the pandemic influenza A(H1N1)v virus from recent human influenza viruses by real-time PCR. PLoS One. 2010;5(4):e9966. doi:10.1371/journal.pone.0009966
   PubMed Web of Science ®Google Scholar
• Rath B, Chen X, Spies V, et al. Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir. Antivir Ther. 2017;22(6):515–522. doi:10.3851/imp3141
   PubMed Web of Science ®Google Scholar
• Zhou B, Donnelly ME, Scholes DT, et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol. 2009;83(19):10309–10313. doi:10.1128/jvi.01109-09
   PubMed Web of Science ®Google Scholar
• Zhou B, Lin X, Wang W, et al. Universal influenza B virus genomic amplification facilitates sequencing, diagnostics, and reverse genetics. J Clin Microbiol. 2014;52(5):1330–1337. doi:10.1128/jcm.03265-13
   PubMed Web of Science ®Google Scholar
• Duwe S, Schweiger B. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J Virol Methods. 2008;153(2):134–141. doi:10.1016/j.jviromet.2008.07.017
   PubMed Web of Science ®Google Scholar
• Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the −2,6-Sialyltransferase in MDCK Cells Increases Influenza Virus Sensitivity to Neuraminidase Inhibitors. J Virol. 2003;77(15):8418–8425. doi:10.1128/jvi.77.15.8418-8425.2003
   PubMed Web of Science ®Google Scholar
• Rath BC, Spies X, Muehlhans V, et al. Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir. Antivir Ther. 2016;22(6):515–522.
   Web of Science ®Google Scholar
• World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility- Geneva, November 2011 and June 2012. Available from: https://apps.who.int/iris/bitstream/handle/10665/241965/WER8739_369-374.PDF?sequence=1&isAllowed=y. Accessed January 26, 2023.
   Google Scholar
• Schmidtke M, Schnittler U, Jahn B, Dahse H, Stelzner A. A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. J Virol Methods. 2001;95(1–2):133–143. doi:10.1016/s0166-0934(01)00305-6
   PubMed Web of Science ®Google Scholar
• Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods. 1988;20(4):309–321. doi:10.1016/0166-0934(88)90134-6
   PubMed Web of Science ®Google Scholar
• Chesnokov A, Patel MC, Mishin VP, et al. Replicative fitness of seasonal influenza a viruses with decreased susceptibility to baloxavir. J Infect Dis. 2020;221(3):367–371. doi:10.1093/infdis/jiz472
   PubMed Web of Science ®Google Scholar
• Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366(9492):1175–1181. doi:10.1016/S0140-6736(05)67338-2
   PubMed Web of Science ®Google Scholar
• Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52(9):3284–3292. doi:10.1128/AAC.00555-08
   PubMed Web of Science ®Google Scholar
• Ciancio BC, Meerhoff TJ, Kramarz P, et al. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007–8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. Euro Surveill. 2009;14(46). doi:10.2807/ese.14.46.19412-en
   Google Scholar
• Takashita E, Meijer A, Lackenby A, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014. Antiviral Res. 2015;117:27–38. doi:10.1016/j.antiviral.2015.02.003
   PubMed Web of Science ®Google Scholar
• Hurt AC, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015. Antiviral Res. 2016;132:178–185. doi:10.1016/j.antiviral.2016.06.001
   PubMed Web of Science ®Google Scholar
• Taieb V, Ikeoka H, Ma FF, et al. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. Curr Med Res Opin. 2019:1–10. doi:10.1080/03007995.2019.1584505
   Web of Science ®Google Scholar
• Vasiliy PM, Mira CP, Anton C, et al. Susceptibility of influenza A, B, C, and D viruses to baloxavir. Emerg Infect Dis J. 2019;25(10). doi:10.3201/eid2510.190607
   Web of Science ®Google Scholar
• Abed Y, Fage C, Checkmahomed L, Venable MC, Boivin G. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice. Antivir Res. 2020;179:104807. doi:10.1016/j.antiviral.2020.104807
   PubMed Web of Science ®Google Scholar
• Imai M, Yamashita M, Sakai-Tagawa Y, et al. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets. Nature Microbiol. 2020;5(1):27–33. doi:10.1038/s41564-019-0609-0
   PubMed Web of Science ®Google Scholar
• Sato M, Takashita E, Katayose M, et al. Detection of variants with reduced baloxavir marboxil susceptibility after treatment of children with influenza A during the 2018–2019 influenza season. J Infect Dis. 2020;222(1):121–125. doi:10.1093/infdis/jiaa061
   PubMed Web of Science ®Google Scholar
• Omoto S, Speranzini V, Hashimoto T, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8(1):9633. doi:10.1038/s41598-018-27890-4
   PubMed Web of Science ®Google Scholar
• Takashita E, Ichikawa M, Morita H, et al. Human-to-Human Transmission of Influenza A(H3N2) virus with reduced susceptibility to baloxavir, Japan, February 2019. Emerg Infect Dis. 2019;25(11):2108–2111. doi:10.3201/eid2511.190757
   PubMed Web of Science ®Google Scholar
• Takashita E, Kawakami C, Ogawa R, et al. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Euro Surveill. 2019;24(12). doi:10.2807/1560-7917.es.2019.24.12.1900170
   Google Scholar
• Valenciano M, Ciancio BC; on behalf of the I-MOVE study team C. I-MOVE: a European network to measure the effectiveness of influenza vaccines. Eurosurveillance. 2012;17(39):20281. doi:10.2807/ese.17.39.20281-en
   Web of Science ®Google Scholar
• Imoveflu. Preliminary influenza vaccine effectiveness estimates for 2021–22. I-Move 2020; 2022. Available from: https://www.imoveflu.org/news/. Accessed December 1, 2022.
   Google Scholar
• Rose A, Kissling E, Emborg H-D, et al. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Eurosurveillance. 2020;25(10):2000153. doi:10.2807/1560-7917.ES.2020.25.10.2000153
   Web of Science ®Google Scholar